The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and Mitigation Strategy. The proposal would require that certain solid oral dosage forms of immediate-release opioid analgesics commonly prescribed to treat acute pain be made available in fixed-quantity blister packaging for outpatient dispensing. “This could reduce the amount of unused opioid analgesics, thereby reducing opportunities for misuse, abuse, inappropriate access and overdose, and possibly reducing the development of new opioid addiction,” the agency said. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 allows the FDA to require special packaging for opioids and other drugs that pose a risk of abuse or overdose. 

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…